A multimodal evaluation of transcranial photobiomodulation in mild cognitive impairment: Cognitive, metabolic, and neuroimaging outcomes of a pilot randomized controlled trial
Journal of Alzheimer’s Disease · 2026-08 · 112 (3) · 1445-1458
DOI: 10.1177/13872877261453911 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 03.06.2026. Verfasst von Neda Rashidi-Ranjbar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Low-Level Light Therapy, Cognitive Dysfunction, Cognition. Die Arbeit nennt 59 Literaturangaben. Gefördert von: Hilary and Galen Weston Foundation, Temerty-Tanz-TDRA, TDRA-MITO2i.
Abstract (Originalsprache)
Background
Mild cognitive impairment (MCI), a prodromal stage of Alzheimer's disease and related dementias (ADRD), represents a critical window for intervention. Although mitochondrial dysfunction is increasingly implicated in neurodegeneration, most therapies target downstream protein aggregation. Transcranial photobiomodulation (tPBM) delivers near-infrared light to enhance mitochondrial respiration.
Objective
We hypothesized that tPBM in MCI would be safe, feasible, and associated with improvements in cognition, mitochondrial function, and default mode network (DMN) functional connectivity (FC).
Methods
We conducted a single-blind, randomized, sham-controlled pilot trial (NCT05563298) in adults ≥50 years with MCI. Twenty participants were randomized 1:1 to active or sham devices. Active devices delivered pulsed 810-nm light for 20 min per session; shams emitted light for 2 seconds. Stimulation targeted DMN hubs and the olfactory bulb. Participants self-administered treatment at home six days per week for six weeks.
Results
Adherence was high (active 96.9%; sham 94.2%). Adverse events (AEs) were reported by 10 of 20 participants (4 active, 6 sham). No serious AEs occurred. Compared with sham, active tPBM produced greater improvement in global cognition (Mini-Mental State Examination; p = 0.03, d = 1.05) and episodic memory (California Verbal Learning Test-II long-delay recognition; p = 0.02, d = 1.09). Serum pyruvate and lactate increased with a reduced lactate-to-pyruvate (L/P) ratio (p = 0.007, d = -1.37). DMN FC increased (p = 0.014, d = 1.25), and plasma IL-6 declined (p = 0.02, r = -0.52).
Conclusions
Home-based tPBM was safe, well tolerated, and feasible, with high adherence and mild AEs. Cognitive, metabolic, and network-level findings are consistent with enhanced mitochondrial efficiency and anti-inflammatory effects. These results support larger, double-blind, multicenter trials to evaluate tPBM as a mitochondria-targeted therapy in early ADRD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, ON, Canada.
- Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.
- Temerty Faculty of Medicine, Department of Surgery, University of Toronto, Toronto, ON, Canada.
- Temerty Faculty of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
- Temerty Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
- Department of Pharmacology & Toxicology, Mitochondrial Innovation Initiative, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Neda Rashidi-Ranjbar, Reza Zomorrodi, Tarek K Rajji, David G Munoz, Tom A Schweizer, Corinne E Fischer
Förderung
- Hilary and Galen Weston Foundation
- Temerty-Tanz-TDRA
- TDRA-MITO2i
Zitieren
APA
Rashidi-Ranjbar, N., Churchill, N. W., Jerkic, M., Zomorrodi, R., Rotstein, O., Schneider, R., Andreazza, A. C., Rajji, T. K., Graham, S. J., Munoz, D. G., Fornazzari, L., Lim, L., Norris, M., Schweizer, T. A., & Fischer, C. E. (2026). A multimodal evaluation of transcranial photobiomodulation in mild cognitive impairment: Cognitive, metabolic, and neuroimaging outcomes of a pilot randomized controlled trial. Journal of Alzheimer’s Disease, 112(3), 1445-1458. https://doi.org/10.1177/13872877261453911
Vancouver
Rashidi-Ranjbar N, Churchill NW, Jerkic M, Zomorrodi R, Rotstein O, Schneider R, et al. A multimodal evaluation of transcranial photobiomodulation in mild cognitive impairment: Cognitive, metabolic, and neuroimaging outcomes of a pilot randomized controlled trial. Journal of Alzheimer’s Disease. 2026;112(3):1445-1458. doi:10.1177/13872877261453911
BibTeX
@article{RashidiRanjbar2026,
author = {Rashidi-Ranjbar, Neda and Churchill, Nathan W and Jerkic, Mirjana and Zomorrodi, Reza and Rotstein, Ori and Schneider, Raphael and Andreazza, Ana C and Rajji, Tarek K and Graham, Simon J and Munoz, David G and Fornazzari, Luis and Lim, Lew and Norris, Mireille and Schweizer, Tom A and Fischer, Corinne E},
title = {A multimodal evaluation of transcranial photobiomodulation in mild cognitive impairment: Cognitive, metabolic, and neuroimaging outcomes of a pilot randomized controlled trial},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
volume = {112},
number = {3},
pages = {1445--1458},
doi = {10.1177/13872877261453911}
}
EUVIMED